Eisai Co., Ltd. and Merck, through a subsidiary, have entered a clinical trial collaboration to evaluate the safety, tolerability and efficacy of Merck’s anti-PD-1 therapy, pembrolizumab (KEYTRUDA), in combination with Eisai oncology compounds lenvatinib mesylate (a multi-targeting RTK inhibitor marketed in the U.S. as LENVIMA) and eribulin mesylate (a microtubule dynamics inhibitor marketed as HALAVEN) in multiple clinical trials. The studies, expected to begin in 2H15, include a Phase Ib/II s...